Breaking
FDA approves Camizestrant for breast cancer with ESR1 mutationsAdjunct Antipsychotics Offer Hope for Depression TreatmentMountain West Cancer Care Hampered by Distance, TelehealthNew Drug Reduces Heart Attack RiskMyasthenia Gravis Patients Live Longer Than Multiple SclerosisFDA approves Rusfertide for erythrocytosis in polycythemia vera

metastatic breast cancer

FDA approves Camizestrant for breast cancer with ESR1 mutations
Gut Health

FDA approves Camizestrant for breast cancer with ESR1 mutations

The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment option and its clinica

Seraphina Wentworth · September 5, 2026